ATHENEX INC (NASDAQ:ATNX) announced its quarterly earnings data on Monday. The company reported ($0.88) earnings per share (EPS) for the quarter, Morningstar.com reports.
Shares of ATHENEX INC (ATNX) opened at 15.44 on Tuesday. ATHENEX INC has a 12 month low of $11.21 and a 12 month high of $20.79. The company has a 50-day moving average price of $16.84 and a 200-day moving average price of $16.35. The company’s market capitalization is $628.19 million.
Separately, Deutsche Bank AG started coverage on ATHENEX INC in a research note on Monday, July 10th. They issued a “buy” rating and a $20.00 price objective on the stock.
In related news, CEO Johnson Yiu Nam Lau acquired 25,200 shares of the stock in a transaction on Monday, June 19th. The stock was acquired at an average cost of $11.00 per share, for a total transaction of $277,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,722,722 shares of the company’s stock, valued at approximately $29,949,942. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Song-Yi Zhang acquired 328,637 shares of the stock in a transaction on Monday, June 19th. The stock was bought at an average price of $11.00 per share, with a total value of $3,615,007.00. Following the completion of the acquisition, the director now directly owns 4,000 shares of the company’s stock, valued at $44,000. The disclosure for this purchase can be found here.
Hedge funds have recently modified their holdings of the company. Laurion Capital Management LP bought a new stake in shares of ATHENEX INC during the second quarter valued at approximately $1,600,000. OxFORD Asset Management LLP bought a new stake in shares of ATHENEX INC during the second quarter valued at approximately $956,000. California Public Employees Retirement System bought a new stake in shares of ATHENEX INC during the second quarter valued at approximately $800,000. Vanguard Group Inc. bought a new stake in shares of ATHENEX INC during the second quarter valued at approximately $800,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of ATHENEX INC during the second quarter valued at approximately $601,000. Institutional investors and hedge funds own 0.14% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “ATHENEX INC (ATNX) Posts Earnings Results” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://stocknewstimes.com/2017/08/14/athenex-inc-atnx-posts-quarterly-earnings-results.html.
About ATHENEX INC
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Receive News & Ratings for ATHENEX INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ATHENEX INC and related companies with MarketBeat.com's FREE daily email newsletter.
